[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15132
1. Wang ZY, Sun LW, Wu JL, Li L, Ma JM, Hu JD: Management of Malignant Gastric Outlet Obstruction with Expandable Metallic Stent Placement. Gastroenterology Res; 2008 Dec;1(1):40-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Malignant Gastric Outlet Obstruction with Expandable Metallic Stent Placement.
  • BACKGROUND: To investigate the efficacy and procedural skills of metallic stent placement for malignant gastric outlet obstruction.
  • METHODS: Nine patients with malignant gastric outlet obstruction were performed metallic stent placement.
  • The common post-procedural complications included nausea, vomiting, upper digestive tract hemorrhage and upper abdominal pain.
  • CONCLUSIONS: Expandable metallic stents placed in patients with malignant obstruction of gastric outlet effectively palliate the obstructive symptoms.
  • Technical skills play important roles in stent placement in treatment of malignant gastric outlet obstruction, and the efficacy of metallic stent placement is associated with the location of metallic stents and therapeutic indications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994705.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; efficacy / expandable metallic stent / gastric cancer / gastric outlet / obstruction / placement / technique skills
  •  go-up   go-down


2. Greven WL, van Bemmel T: Rare oxygen, a rare way to diagnose Conn's syndrome. NDT Plus; 2008 Dec;1(6):427-428

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A CT scan of the abdomen revealed an adenoma in the left adrenal gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2003 Apr 26;326(7395):915-9 [12714473.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10):789-800 [15545679.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):607-18 [17492946.001]
  • (PMID = 28657013.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Conn's syndrome / hyperaldosteronism / mountain sickness
  •  go-up   go-down


3. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • The most common early complications were: macroscopic haematuria, pain in lower part of the abdomen, and transient dysuria.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


Advertisement
4. Zugates GT, Peng W, Zumbuehl A, Jhunjhunwala S, Huang YH, Langer R, Sawicki JA, Anderson DG: Rapid Optimization of Gene Delivery by Parallel End-modification of Poly(β-amino ester)s. Mol Ther; 2007 Jul;15(7):1306-1312

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo, intraperitoneal (IP) gene delivery using end-modified C32 polymers resulted in expression levels over one order of magnitude higher than unmodified C32 and jet-polyethylenimine (jet-PEI) levels in several abdominal organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182918.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Mercadante S, Villari P, Casuccio A, Marrazzo A: A randomized-controlled study of intrathecal versus epidural thoracic analgesia in patients undergoing abdominal cancer surgery. J Clin Monit Comput; 2008 Aug;22(4):293-8
Hazardous Substances Data Bank. LIDOCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized-controlled study of intrathecal versus epidural thoracic analgesia in patients undergoing abdominal cancer surgery.
  • BACKGROUND: We sought to determine the effectiveness of continuous intrathecal thoracic analgesia (ITA) in comparison with continuous epidural thoracic analgesia (ETA) for the management of postoperative pain after abdominal cancer surgery in a randomised controlled study.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Analgesia, Epidural / methods. Injections, Spinal / methods. Lidocaine / administration & dosage. Pain Measurement / drug effects. Pain, Postoperative / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685961.001).
  • [ISSN] 1387-1307
  • [Journal-full-title] Journal of clinical monitoring and computing
  • [ISO-abbreviation] J Clin Monit Comput
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anesthetics, Local; 98PI200987 / Lidocaine
  •  go-up   go-down


6. Dravid RM, Paul RE: Interpleural block - part 1. Anaesthesia; 2007 Oct;62(10):1039-49

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interpleural blockade is effective in treating unilateral surgical and nonsurgical pain from the chest and upper abdomen in both the acute and chronic settings.
  • It has also been used successfully in the treatment of pain from multiple rib fractures, herpes zoster, complex regional pain syndromes, thoracic and abdominal cancer, and pancreatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anaesthesia. 2008 May;63(5):551; author reply 551-2 [18412659.001]
  • [CommentIn] Anaesthesia. 2008 May;63(5):552-3; author reply 553 [18412660.001]
  • [CommentIn] Anaesthesia. 2008 May;63(5):553 [18412662.001]
  • [ErratumIn] Anaesthesia. 2007 Nov;62(11):1197
  • (PMID = 17845657.001).
  • [ISSN] 0003-2409
  • [Journal-full-title] Anaesthesia
  • [ISO-abbreviation] Anaesthesia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Local
  • [Number-of-references] 73
  •  go-up   go-down


7. McDermott A: Starting out-It was a privilege to meet the cultural needs of dying patient. Nurs Stand; 2010 Nov 03;25(9):29

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had breast cancer with metastasis, and had been admitted to the acute medical ward with abdominal pain, vomiting and breathlessness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28026442.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Krastev Z, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W: Locoregional IL-2 low dose applications for gastrointestinal tumors. World J Gastroenterol; 2005 Sep 21;11(35):5525-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer.
  • CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222748.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0 / Recombinant Proteins; M89N0Q7EQR / aldesleukin
  • [Other-IDs] NLM/ PMC4320365
  •  go-up   go-down


9. Tzedakis A, Damilakis J, Perisinakis K, Stratakis J, Gourtsoyiannis N: The effect of z overscanning on patient effective dose from multidetector helical computed tomography examinations. Med Phys; 2005 Jun;32(6Part1):1621-1629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A commercially available mathematical anthropomorphic phantom was used for the estimation of effective doses from four standard CT examinations, i.e., head and neck, chest, abdomen and pelvis, and trunk studies.
  • The percentage differences in the normalized effective dose between contiguous axial and helical scans with pitch=1, may reach 13.1%, 35.8%, 29.0%, and 21.5%, for head and neck, chest, abdomen and pelvis, and trunk studies, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28513942.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Ancillary equipment / Collimation / Computed radiography / Computed tomography / Dosimetry / Dosimetry/exposure assessment / Image analysis / Image scanners / Ionization chambers / Medical image reconstruction / Medical imaging / Monte Carlo methods / Tissues / biological tissues / computerised tomography / dosimetry / image reconstruction / ionisation chambers / medical image processing / thermoluminescent dosimeters
  •  go-up   go-down


10. McDermott S, Skehan SJ: Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT. Abdom Imaging; 2010 Feb;35(1):55-69
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT.
  • Proper interpretation of PET-CT images requires knowledge of the normal physiological distribution of the tracer, frequently encountered physiological variants, and benign pathological causes of FDG uptake that can be confused with a malignant neoplasm.
  • In addition, not all malignant processes are associated with avid tracer uptake.
  • This article reviews these potential pitfalls as they apply to the abdomen and pelvis of patients with cancer.
  • [MeSH-major] Abdominal Neoplasms / radiography. Abdominal Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130117.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 30
  •  go-up   go-down


11. Gnanasambandam S, Olsen ØE: CT in children with abdominal cancer: should we routinely include the pelvis? Pediatr Radiol; 2006 Mar;36(3):213-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT in children with abdominal cancer: should we routinely include the pelvis?
  • BACKGROUND: It has been suggested that the pelvis should not be habitually included on abdominal CT examinations, but the potential benefit of such a practice in childhood abdominal malignancies is unknown.
  • OBJECTIVE: To estimate the yield and potential diagnostic benefit of abnormal findings on CT of the pelvis in children with malignant primary tumours in the upper abdomen.
  • MATERIALS AND METHODS: From a paediatric tertiary referral hospital we retrospectively included patients having abdominal CT for primary upper abdominal tumours (1997-2004), the scan range routinely including the pelvis.
  • CONCLUSIONS: Our data suggest that diagnostically significant findings in the pelvis are rare; consequently, the habitual inclusion of the pelvis on abdominal CT for primary malignant tumours in the abdomen is not justified.
  • [MeSH-major] Abdominal Neoplasms / radiography. Pelvis / radiography. Radiography, Abdominal / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331450.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Hillbrand M, Georg D, Gadner H, Pötter R, Dieckmann K: Abdominal cancer during early childhood: a dosimetric comparison of proton beams to standard and advanced photon radiotherapy. Radiother Oncol; 2008 Nov;89(2):141-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal cancer during early childhood: a dosimetric comparison of proton beams to standard and advanced photon radiotherapy.
  • PURPOSE: Evaluation of dosimetric benefits of advanced radiotherapy techniques for the treatment of abdominal lesions during early childhood.
  • PATIENTS AND METHODS: Treatment planning was performed for five Neuroblastoma (NBL) and four Wilms Tumor (WT) patients.
  • The risk for radiation-induced secondary cancer was doubled for IMXT and even more increased for PT if secondary neutrons were taken into account, while this risk remained the same or was reduced by IMPT with respect to 2F.
  • Further research is needed to minimize uncertainties for secondary cancer estimations.
  • [MeSH-major] Abdominal Neoplasms / radiotherapy. Kidney Neoplasms / radiotherapy. Neuroblastoma / radiotherapy. Wilms Tumor / radiotherapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692928.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


13. Ahunbay EE, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA: An on-line replanning scheme for interfractional variationsa). Med Phys; 2008 Aug;35(8):3607-3615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The entire scheme was tested for direct-aperture-based IMRT on representative prostate and abdomen cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28525032.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Cone beam computed tomography / Dose-volume analysis / Dosimetry / IGRT / Intensity modulated radiation therapy / Medical image segmentation / Medical imaging / Multileaf collimators / Optimization / Self assembly / adaptive radiotherapy / image segmentation / interfractional variations / planning / radiation therapy / replanning
  •  go-up   go-down


14. Levy MJ, Wiersema MJ: Endoscopic ultrasound-guided pain control for intra-abdominal cancer. Gastroenterol Clin North Am; 2006 Mar;35(1):153-65, x
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided pain control for intra-abdominal cancer.
  • [MeSH-major] Abdominal Neoplasms / complications. Analgesia / methods. Autonomic Denervation / methods. Celiac Plexus / ultrasonography. Endoscopy. Pain / etiology. Pain Management

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530118.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


15. Mekhail T, Rich T, Rosen L, Chai F, Semic-Suka Z, Savage RE, Senzer N: Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3548 Background: ARQ 197 is a selective, non-ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in tumor cell migration, invasion, and proliferation.
  • RESULTS: To date, 65 pts (38 male/27 female; median age 61; 9 colon/colorectal, 8 renal cell carcinoma/kidney, 6 ovarian, 6 sarcoma, 5 lung cancer and 31 others) have been treated at 11 dose levels (10 mg bid to 360 mg bid).
  • One case each of the following drug-related serious AEs were reported in 4 pts: anemia, leukopenia, neutropenia, thrombocytopenia, dehydration, liver failure, abdominal pain, nausea, and vomiting.
  • Three pts with neuroendocrine, prostate, or testicular cancer achieved a partial response (PR), 32 demonstrated stable disease (SD) and 13 progressed.
  • Preliminary evidence of anti-cancer activity was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961350.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Shankar V, Haritha C, Trivedi HL, Vanikar A, Modi PM, Shah P, Shah V: Radiation dose-benefit analysis of hematopoietic stem cell grafting for tolerence induction across MHC barriers in living related donor renal allograft recipients. J Clin Oncol; 2009 May 20;27(15_suppl):3044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent subtotal lymphoid irradiation (STLI) targeting spleen, abdominal, iliac and inguinal lymph nodes, thoraco-lumbar vertebra and 75% of pelvis.
  • Tolerance - Robust (R), Prope (P) and Metastable (M) is defined as RT: Stable allograft function (fn.) for >100 days without ISp; PT: Early adequate, stable grafts fn. with no rejection episodes on minimum ISp; MT: Adequate graft fn. on ISp with single episode of steroid responsive ac. rejection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Giles FJ, O'Brien S, Rizzieri DA, Vey N, Krug U, Sekeres M, Jacobsen TF, Nilsson BI, Staudacher K: A phase II study with CP-4055 in patients with second salvage AML. J Clin Oncol; 2009 May 20;27(15_suppl):7047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most frequently reported related AE ≥ grade 3 (CTCAE v3.0) were myelosuppression, abdominal pain, colitis, diarrhoea, nausea, fatigue, liver function test (LFT) elevation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kingsley E, Richards D, Garbo L, Gersh R, Robbins G, Leopold L, Brill J, Di Bella N: An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol; 2009 May 20;27(15_suppl):8582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is active as a single agent and in combination with R in NHL tumor models.
  • Grade 3/4 AEs that occurred in ≥2 pts: nausea 4(17%), vomiting 2(9%), abdominal pain 2(9%), fatigue 2(9%), and small bowel obstruction 2(9%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Plotkin SR, Singh M, Cai W, O'Donnell C, Esparza S, Smith MJ, Harris GJ, Muzikansky A, Bredella MA, Kassarjian A: Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes. J Clin Oncol; 2009 May 20;27(15_suppl):2074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes.
  • A rapid and sensitive method to detect internal tumors is highly desirable since they can cause neurologic dysfunction, compress vital structures, or transform into malignant tumors.
  • The number and type of tumors (discrete vs. plexiform) were identified by a board-certified radiologist and tumor volume was calculated using semi-automated analysis.
  • Sixty-one percent of subjects had ≥1 internal tumor.
  • Overall, the legs harbored the greatest number of tumors (33%), followed by the pelvis (18%), thorax (15%), abdomen (12%), arms (10%), and head/neck (7%).
  • Only 40% of internal tumors were classified as plexiform yet these tumors contributed 78% of the tumor burden by volume.
  • In addition, WBMRI may prove useful in identifying individual patients at high risk for complications (such as neurologic dysfunction or malignant transformation) due to heavy internal tumor burden and in determining the efficacy of antitumor drugs in this unique patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hariprasad R, Kumar L, Kumar S, Bhatla N, Thulkar S, Das P: Advanced epithelial ovarian cancer (EOC): Is there a place for maintenance therapy in patients with sub-optimal debulking? J Clin Oncol; 2009 May 20;27(15_suppl):e14580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced epithelial ovarian cancer (EOC): Is there a place for maintenance therapy in patients with sub-optimal debulking?
  • : e14580 Background: Survival of patients with advanced epithelial ovarian cancer (EOC) with initial suboptimal debulking surgery (residual disease (>1 cm) and those with recurrent EOC is poor.
  • Serum CA-125 was done once in 2 months and CAT scan of abdomen & pelvis every 6 month.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. van der Veldt A, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E: Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. J Clin Oncol; 2009 May 20;27(15_suppl):5044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
  • : 5044 Background: Sunitinib (SU) has been approved for the treatment of metastatic renal cell cancer (mRCC).
  • Since SU can induce extensive necrosis, RECIST may be inappropriate for tumor response evaluation.
  • Imaging data consisted of thoracic and abdominal helical CT scans at baseline, after a median of 2 months and were repeated during treatment.
  • According to Choi criteria partial response (PR) was defined as ≥10% decrease in size or ≥15% decrease in density, while progressive disease (PD) was defined as ≥10% increase in size without meeting PR criteria by density.
  • RESULTS: For RECIST and Choi criteria, respectively, 230 and 156 tumor lesions were eligible.
  • The median tumor density decreased significantly (Wilcoxon Signed Ranks test, p ≤ 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Samelis GF, Tsiakou A, Karamanidi M, Pelechrini M, Zaganides A, Ekmektzoglou K: Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival. J Clin Oncol; 2009 May 20;27(15_suppl):e15143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival.
  • : e15143 Background: The management of patients with metastatic colorectal cancer (mCRC) has evolved dramatically over the last decade, with several "targeted" agents having entered the treatment arena.
  • METHODS: We evaluated the efficacy and safety of bevacizumab in combination with standard chemotherapy (irinotecan, capecitabine, oxaliplatin, cetuximab) in 21 patients with metastatic colorectal cancer with a median age of 69 (range: 47-85) years old with PS: 0-1, included in the study.
  • The metastatic sites were liver in 13 patients, liver and lung in 4 patients, lung in 2 patients, intra-abdominal in 1 patient and urinary-bladder in 1 patient.
  • Subgroup analysis was performed in terms of age, site of metastases, spread and co-morbidity.
  • CONCLUSIONS: Multiple line treatment in advanced colorectal cancer, including bevacizumab combined with standard chemotherapy, may improve OS (median: 23+ months) with an acceptable toxicity profile in patients with mCRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mano M, Hendlisz A, Machiels J, Ehrnrooth E, Aladdin H, Van Laethem J: Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy.
  • In total, 6 patients experienced one or more grade 3/4 toxicities (diarrhea 2; neutropenia 2; leucopenia 1; abdominal pain 1; pulmonary embolism 1; alopecia 1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964396.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Meyniel J, Cottu PH, Stern M, Lebigot I, Mignot L, Roman-Roman S, Sastre-Garau X: A genomic and transcriptomic approach to distinguish primary and metastatic ovary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22150 Background: Distinction of primary ovarian tumors from metastatic tumors involving the ovary is in some cases challenging for final pathologic diagnosis and for treatment with efficient chemotherapy Methods: We gathered from our biobank 16 pairs of breast/ovarian tumors for some of which the diagnosis was uncertain.
  • We investigated the possibility to improve diagnosis using genomic and transcriptomic tools.
  • RESULTS: Primary infiltrating lobular carcinoma (ILC) was observed in 6 patients, infiltrating ductal carcinoma (IDC) in 7 patients, 1 patient had one ILC and one IDC, 1 patient had a mixed IDC+ILC and 1 patient an undifferentiated cancer.
  • Median time to diagnosis of ovarian tumor was 54 months.
  • Ovarian tumors were considered as primary in 7 patients, and metastatic in 9 patients, and diagnosis was ambiguous in 4 of them.
  • Four patients developed extra-abdominal metastases.
  • Median survival from breast cancer diagnosis was 78 months, and from ovarian tumor diagnosis was 29 months.
  • In 4 cases, the genomic profiles established clearly the status of the ovary tumor whereas the pathological analysis did not.
  • CONCLUSIONS: We clearly established in this training series that CGH array analysis could help to discriminate between primary and secondary ovarian tumors from breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963541.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Guida M, Porcelli G, Ruggieri E, Zito A, Mattioli V, Montemurro S, Colucci G: Electrochemoterapy (ECT) for the treatment of superficial tumor localizations. J Clin Oncol; 2009 May 20;27(15_suppl):e13526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemoterapy (ECT) for the treatment of superficial tumor localizations.
  • : e13526 Background: ECT is an effective local treatment for palliation on inoperable superficial neoplastic lesions from any type of tumour.
  • METHODS: We treated 26 pts, M/F 12/14; median age 61 yrs, range 38-87: 7 breast cancer with nodular or infiltrating lesions in thoracic or abdominal wall; 12 melanoma (2 wide infiltration of thoracic wall, 10 in transit metastases or loco-regional recurrences); 2 head-neck cancer with a wide neck-scalp infiltration; 3 lymphomas with cutaneous lesions, 1 soft tissue sarcoma with a subcutaneous recurrence, 1 gastric cancer with 2 cutaneous localizations.
  • Intravenous bleomycin (15 mg/m<sup>2</sup>) were used in all patient; electric pulses were than applied to the tumor areas by needle electrodes in a time window of 20 minutes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Gujral K, Petryk A, Steffen L, Baker K, Perkins J, Kelly AS, Zhou X, Sinaiko A, Moran A, Steinberger J: Growth hormone deficiency and cardiovascular risk factors in childhood cancer survivors. J Clin Oncol; 2009 May 20;27(15_suppl):6614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone deficiency and cardiovascular risk factors in childhood cancer survivors.
  • : 6614 Background: Childhood cancer survivors (CCS) have a high frequency of growth hormone deficiency (GHD) and risk of early cardiovascular disease (CVD).
  • METHODS: Anthropometrics, blood pressure, lipids, growth hormone (GH) stimulation test, dual-energy x-ray absorptiometry, abdominal CT, and insulin resistance (IR) (euglycemic, hyperinsulinemic clamp - low M/lbm signifies IR) were obtained in 174 CCS, mean age 15±2 years and 89 healthy sibling controls, mean age 13.5±3 years.
  • These study findings imply that CVD risk factors are present in CCS with GHD independent of body fatness, suggesting that the cancer diagnosis or treatments received may lead to early cardiovascular disease in childhood cancer survivors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961768.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Viret F, Ychou M, Baey C, Bennouna J, Adenis A, Peiffert D, Mornex F, Celier P, Montoto-Grillot C, Ducreux M: A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.
  • RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.
  • Location of the tumor: head (33 pts), body (13 pts), and tail (5 pts).
  • 30 pts experienced at least one episode of grade 3 or 4 toxicity (asthenia 12 pts, anorexia 11 pts, vomiting 10 pts, nausea 9 pts, abdominal pain 5 pts).
  • Grant by sanofi-aventis, Amgen, and Ligue Nationale Contre Le Cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Limentani SA, Awada A, Dirix L, Beck J, Dieras V, Binlich F, Germa C, Agrapart V, Powell C, Hershman D: Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preclinical studies have shown synergistic antitumor activity with the combination of trastuzumab plus vinorelbine in metastatic breast cancer.The recommended dose of neratinib in monotherapy is 240 mg.
  • Tumor measurements were made every 6 wks by modified RECIST criteria.
  • AEs, any causality, all grades in ≥ 15% of pts included diarrhea (92%), nausea (67%), constipation (50%), fatigue (42%), vomiting and anthralgia (33% each), abdominal pain and anorexia, (25% each), anemia and neutropenia (17% each).
  • Preliminary efficacy data show that 1 pt with stomach cancer had stable disease, lasting ≥21 weeks.
  • CONCLUSIONS: The combination of 240 mg neratinib and 25 mg/m<sup>2</sup> vinorelbine was found to be tolerable and to demonstrate early evidence of clinical benefit in pts with solid tumors, to be assessed further in pts with metastatic ErbB-2+ breast cancer in part 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Phase 2 Consortium: Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.
  • : 3521 Background: Systemic therapies have had little impact on the outcomes of patients with advanced differentiated thyroid cancers.
  • METHODS: A three-outcome one-stage Phase II trial was conducted to assess the anti-tumor activity and toxicities of the orally bioavailable VEGF/tyrosine kinase inhibitor pazopanib (800 mg daily) in patients with advanced and progressive radioiodine-insensitive differentiated thyroid cancers.
  • Six patients (23%) required dose reduction due to: grade 2+ ALT (3 pts), grade 3 mucositis (1 pt); grade 3 diarrhea and dehydration (1 pt), and grade 3 abdominal pain (1 pt.).
  • CONCLUSIONS: Pazopanib appears to have both a favorable toxicity profile and promising clinical activity in patients with advanced and progressive differentiated thyroid cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC: Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol; 2009 May 20;27(15_suppl):10017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At IRN 50 mg/m<sup>2</sup>/day, 4/12 pts had DLT (hepatotoxicity, abdominal pain, anorexia, hypokalemia, and thrombocytopenia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962502.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Contreras CM, Badgwell BD, Askew RL, Feig BW, Cormier JN: Radiographic and clinical factors associated with improved outcomes in cancer patients with bowel obstruction. J Clin Oncol; 2009 May 20;27(15_suppl):e20564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and clinical factors associated with improved outcomes in cancer patients with bowel obstruction.
  • : e20564 Background: The purpose of this study was to identify clinical and radiographic factors relevant to treatment outcomes in cancer patients presenting with bowel obstruction.
  • RESULTS: Of 194 patients, 25% had a primary diagnosis of colorectal cancer.
  • Computed tomography, plain radiographs, enteral contrast studies, and other modalities were used for diagnosis in 59%, 26%, 12%, and 3% of patients, respectively.
  • Additional relevant clinical factors affecting OS included serum albumin level; however, no association was observed for age, tumor type, site of obstruction, previous bowel obstruction, or abdominal exploration.
  • CONCLUSIONS: Clinical and radiographic factors affect treatment outcomes for cancer patients with bowel obstruction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Surgery (performed in 14 patients) consisted of low anterior resection in 5pts and abdominal-perineal resection in 10p.
  • Tumor down-staging was observed in 10pts (66.6%), including 5pts with complete pathological response (33.3%).
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gardner K, Judson I, Leahy M, Barquin E, Marotti M, Collins B, Young H, Scurr M: Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response to conventional chemotherapy is poor (overall response rates are approximately 7% [Reichardt P et al,Eur J Cancer.2003;39:1511-1516]).
  • RESULTS: Median age at diagnosis was 39 years (range: 26-49).
  • All patients had pulmonary metastases and two had additional sites of disease (brain, bone, intra-abdominal) at study entry.
  • Four patients had a best response of partial response, two patients had a confirmed reduction in maximum tumor diameter of ≥10% and <30% and one patient experienced stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963912.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Oaknin AM, Romeo M, Pons F, Perez X, Barretina P, Vidal A, Martí L, Barahona M, Germá J, Ponce J: Behavior of borderline ovarian tumours (BOTs): Single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 6 patients (7.8%) with noninvasive implants involving abdominal peritoneum (1), pelvic peritoneum (1), omentum (2) and both pelvic peritoneum and omentum (2).
  • All were stage I disease at diagnosis.
  • Histology recurrences were: 2 borderline, 2 invasive ovarian cancer, and 1 unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961533.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Olmos D, Allred A, Sharma R, Brunetto A, Smith D, Murray S, Barker D, Taegtmeyer A, de Bono J, Blagden S: Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3536 Background: Polo-like kinase-1 (Plk1), part of a family of highly conserved serine-threonine kinases, has multiple roles in mitotic progression, is over-expressed and also associated with poor prognosis in some tumor types.
  • Secondary objectives included preliminary evaluation of anti-tumor activity.
  • Other Sch 1 adverse events (AEs) with a maximum grade ≥3 were fatigue and anemia (both, n = 2), pleuritic pain, pelvic pain, abdominal discomfort, constipation, vomiting, neutropenia, and deep vein thrombosis (all, n = 1).
  • The most common adverse events (AEs) regardless of attribution, Sch and dose level were phlebitis (n = 9), fatigue (n = 9), nausea (n = 7), anemia (n = 6), anorexia (n = 6), diarrhea (n = 6), and infusion site reaction (n = 5).
  • Phospho-histone H3, a marker of mitotic arrest, was detected, in circulating tumor cells, 24 hrs after first dose.
  • Stable disease >5m has been observed in 2 esophageal cancer pts.
  • An MTD has not yet been defined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Konner JA, Grabon D, Pezzulli S, Iasonos A, Sabbatini P, Hensley M, Bell-McGuinn K, Tew W, Spriggs D, Aghajanian C: A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer.
  • : 5539 Background: IP cisplatin (Cis) plus IV/IP paclitaxel (Tax) is a standard therapy for optimally debulked ovarian cancer.
  • Activity of Bev in recurrent ovarian cancer has been reported in phase II trials.
  • METHODS: Patients with optimal (<1 cm residual), FIGO stage II or III, epithelial ovarian, fallopian tube, or peritoneal cancer, acceptable organ function, and KPS ≥ 70% are eligible.
  • There were 3 occurrences of grade 3 abdominal pain (8%); and 3 adhesion-related grade 3 small bowel obstructions (8%), during cycles 3, 9, and 15, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Gerber B, Stehle H, Ricardo F, Maass N, Fischer D, Sommer HL, Conrad B, Mehta K, Loibl S: ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol; 2009 May 20;27(15_suppl):526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37).
  • To prevent related health problems and to maintain fertility after chemotherapy in patients with hormone insensitive breast cancer, ovarian function might be protected by using a GnRH-agonist.
  • METHODS: Patients (pts) < 46 years, with a hormone insensitive breast cancer were randomized to receive an anthracycline/taxane containing chemotherapy with or without goserelin 3.6mg in parallel as subcutaneous injection in the abdominal wall starting at least 2 weeks before chemotherapy, and thereafter every 4 weeks (28 ± 3 days) until the end of the last chemotherapy cycle (EOC).
  • The endpoint normal ovarian function 6 months after EOC is defined by two consecutive menstrual periods within 21-35 days within a time frame of 5-8 months after last application of goserelin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Krasner CN, Poveda A, Herzog T, Vermorken J, Monk B, Zintl P, Li J, Su Y, Dhawan R, Kaye S: Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol; 2009 May 20;27(15_suppl):5526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
  • : 5526 Background: In an open-label, multicenter, randomized phase III study comparing the combination of trabectedin and PLD to PLD alone in patients with relapsed ovarian cancer, the combination demonstrated significantly improved progression free survival and response rates, manageable non-cumulative toxicity, and fewer PLD-associated adverse events.
  • Global health status/QoL, fatigue, rain subscales from QLQ C30, and abdominal pain/GI symptoms scale from OV28 were chosen a priori for primary analyses.
  • CONCLUSIONS: The addition of trabectedin to PLD results in superior efficacy in patients with relapsed ovarian cancer, with no added decrement to overall health status as assessed by PRO.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962478.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Stearns V, Jacobs LK, Tsangaris TN, Briest S, Lange JR, Slater S, Fackler M, Sugar E, Gabrielson E, Davidson NE: A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer.
  • : e14508 Background: Epigenetic modifications contribute to breast cancer initiation and progression and may be reversible, thus representing an attractive area for new drug investigation.
  • In preclinical breast cancer models, the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA, vorinostat) induces cell cycle arrest, apoptosis and differentiation.
  • Baseline and post-treatment tumor specimens were collected for analysis of histone acetylation, candidate gene methylation and expression.
  • One participant took 4 and one 5 doses due to insurance clearance delay; one received a single dose due to fatigue and abdominal pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Yuasa T, Rivas-Carrillo JD, Navarro-Alvarez N, Soto-Gutierrez A, Kubota Y, Tabata Y, Okitsu T, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N: Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2. Cell Transplant; 2009 May/Jun;18(5-6):683-688

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2.
  • We placed the BAP in the abdominal cavity and covered it with the greater omentum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880643.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Bioartificial pancreas / Fibroblast growth factor 2 / Neovascularization
  •  go-up   go-down


41. Park MS, Kim MJ, Lim JS, Kim SH, Kim HS, Chung YE, Kim KW: Metastasis versus focal eosinophilic infiltration of the liver in patients with extrahepatic abdominal cancer: an evaluation with gadobenate dimeglumine-enhanced magnetic resonance imaging. J Comput Assist Tomogr; 2009 Jan-Feb;33(1):119-24
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis versus focal eosinophilic infiltration of the liver in patients with extrahepatic abdominal cancer: an evaluation with gadobenate dimeglumine-enhanced magnetic resonance imaging.
  • MATERIALS AND METHODS: Gadobenate dimeglumine-enhanced MRI conducted in 38 patients (lesions of 43 metastases and 33 FEIs) with extrahepatic abdominal carcinoma were reviewed retrospectively.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / secondary. Eosinophilia / diagnosis. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Meglumine / analogs & derivatives. Organometallic Compounds
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188798.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


42. Brock KK, Sharpe MB, Dawson LA, Kim SM, Jaffray DA: Accuracy of finite element model-based multi-organ deformable image registration. Med Phys; 2005 Jun;32(6Part1):1647-1659

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The feasibility and accuracy of the method was tested on MR thoracic and abdominal images of healthy volunteers at inhale and exhale.
  • For the abdominal cases, the liver, spleen, and external surface were explicitly deformed and the stomach and kidneys were implicitly deformed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28513963.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Bifurcations / Cancer / Clinical applications / Field emitters / Finite element methods / Finite-element and Galerkin methods / Hemodynamics / Image analysis / Image registration / Liver / Lungs / Materials properties / Mechanical and electrical properties of tissues and organs / Medical imaging / Pneumodyamics, respiration / biomechanics / biomedical MRI / finite element analysis / image registration / kidney / liver / lung / medical image processing / pneumodynamics
  •  go-up   go-down


43. Ardalan B, Feagans M, Mezentsev D, Jones C, Subbarayan PR, Walker G, Sapp M, Stephenson K, Ness J, Franceschi D, Livingstone A: Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL). J Clin Oncol; 2009 May 20;27(15_suppl):e15114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL).
  • : e15114 Background: In a previous study, IFL was used in patients (pt) with untreated metastatic colon cancer and a median overall survival (MOS) of 31 months (m).
  • In the current study we added B to IFL to determine toxicity profiles (TP) and the response rate (RR) to the B-IFL regimen.
  • Eligible pt received 2 cycles of B-IFL followed by CT scan.
  • 8 pt (36%) had bilobar liver disease and involvement of 1 other organ, 6 pt (27%) had bilobar liver disease with involvement of ≥ 2 other organs; 5 pt (23.5%) had bilobar liver disease; 2 pt (9%) had abdominal carcinomatosis; 1 pt (4.5 %) had involvement in one liver lobe.
  • Gr 3 occurred in 11 pt (50%); DVT, diarrhea (Drh) 3 pt (14%); fatigue (Ftg), infection, port site thrombosis (Pst), small bowel obstruction 2 pt (9%); wound dehiscence 1pt (5%); Gr 2 and 1: constipation; Drh; Ftg; nausea; neutropenia; Pst; alopecia; anorexia; mucositis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Nobes JP, Langley SE, Laing RW: Use of metformin and lifestyle intervention to prevent ADT-related metabolic syndrome in prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of metformin and lifestyle intervention to prevent ADT-related metabolic syndrome in prostate cancer.
  • : 5159 Background: The association between androgen deprivation therapy (ADT) for prostate cancer and metabolic syndrome has been reported, with insulin resistance as the key to its development.
  • METHODS: Forty men with any stage of prostate cancer, due to receive ADT with a GnRH agonist, were recruited to a prospective randomised pilot study.
  • Men in the intervention arm (n=20) received ADT with 6 months of metformin, a low glycaemic index diet and a regular aerobic exercise programme.
  • The table shows an improvement in abdominal girth, weight, body mass index, and systolic blood pressure in the intervention arm, when measured as a % change over 6 months.
  • CONCLUSIONS: ADT is widely used in prostate cancer, but metabolic complications may be responsible for an increased cardiovascular mortality.
  • However, the anticipated increased incidence of insulin resistance and metabolic syndrome has not been demonstrated in men receiving ADT alone, which may be due to small study size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Wilbert J, Meyer J, Baier K, Guckenberger M, Herrmann C, Heß R, Janka C, Ma L, Mersebach T, Richter A, Roth M, Schilling K, Flentje M: Tumor tracking and motion compensation with an adaptive tumor tracking system (ATTS): System description and prototype testing. Med Phys; 2008 Sep;35(9):3911-3921

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor tracking and motion compensation with an adaptive tumor tracking system (ATTS): System description and prototype testing.
  • A novel system for real-time tumor tracking and motion compensation with a robotic HexaPOD treatment couch is described.
  • The approach is based on continuous tracking of the tumor motion in portal images without implanted fiducial markers, using the therapeutic megavoltage beam, and tracking of abdominal breathing motion with optical markers.
  • In the second part the performance of the HexaPOD couch was investigated with a robotic four-dimensional-phantom capable of simulating real patient tumor trajectories in three-dimensional space.
  • Base line drifts of the mean tumor position of realistic lung tumor trajectories could be fully compensated.
  • For continuous tumor tracking and motion compensation a reduction of tumor motion up to 68% of the original amplitude was achieved.
  • In conclusion, this study demonstrated that it is technically feasible to compensate breathing induced tumor motion in the lung with the adaptive tumor tracking system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28525055.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computer software / Conformal radiation treatment / HexaPOD / Image guided radiation therapy / Kinematics / Linear accelerators / Lungs / Medical imaging / Motion compensation / Pneumodyamics, respiration / Robotics / Therapeutics / Treatment planning / adaptive radiotherapy (ART) / cancer / lung / lung tumor / medical robotics / motion compensation / phantoms / pneumodynamics / radiation therapy / real-time tracking / respiratory motion / tumours
  •  go-up   go-down


46. Saglam S, Bugra D, Kaytan Saglam E, Yamaner S, Asoglu O, Balik E, Oral EN, Sakar B, Kizir A, Kapran Y, Camlica H: Prospective randomized study comparing fourth-week surgery versus eighth- week surgery after neoadjuvant concomitant radiotherapy and infusional 5-FU in T3-4/N0+ rectal cancer: Istanbul R-01 Study. J Clin Oncol; 2009 May 20;27(15_suppl):4131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized study comparing fourth-week surgery versus eighth- week surgery after neoadjuvant concomitant radiotherapy and infusional 5-FU in T3-4/N0+ rectal cancer: Istanbul R-01 Study.
  • : 4131 Background: Prospective randomized study has been designed to compare the efficacy of fourth week surgery (4WS) versus eighth week surgery (8WS) after concomitant neoadjuvant chemoradiotherapy (NeoadjCTRT) on local recurrence and overall survival (OS) in cT3-4/N0+, mid and distal localized (intraperitoneal) rectal cancers.
  • All rectal cancer pts are T3-4/N0+; distal and mid rectum and received 45 Gy conventionally fractionated RT in 25 daily fractions of 1.8 Gy combined with 225 mg/m<sup>2</sup>/day continous infusion 5-FU.
  • Preoperative staging was performed by endorectal USG and /or MRI and abdominal CT.4cycles FUFA is standard as adjuvant treatment after surgery.
  • Important factors for local recurrence and (OS) are having distal rectal tumor and SMP and <2mm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960838.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR, Ramsey CR, Van Herk MB, Vedam SS, Wong JW, Yorke E: The management of respiratory motion in radiation oncology report of AAPM Task Group 76a). Med Phys; 2006 Oct;33(10):3874-3900

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This document is the report of a task group of the AAPM and has been prepared primarily to advise medical physicists involved in the external-beam radiation therapy of patients with thoracic, abdominal, and pelvic tumors affected by respiratory motion.
  • Included in this guide is the recommendation that tumor motion should be measured (when possible) for each patient for whom respiratory motion is a concern.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2006 American Association of Physicists in Medicine.
  • (PMID = 28523749.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Conformal radiation treatment / Dosimetry / Hemodynamics / Intensity modulated radiation therapy / Lungs / Medical imaging / Pneumodyamics, respiration / Pneumodynamics / Quality assurance in radiotherapy / Radiation therapy / Radiation treatment / Wedges and compensators / cancer / pneumodynamics / quality assurance / radiation therapy / tumours
  •  go-up   go-down


48. Camargo VP, Maki RG: Clinical outcomes of systemic therapy for patients with desmoids. J Clin Oncol; 2009 May 20;27(15_suppl):10585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intra-abdominal primary location was most common (29/70=41%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • : e15588 Background: This prospective study was performed to assess the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) with three drugs in patients with curative resection of T3 or T4 advanced gastric cancer.
  • METHODS: Patients with curative resection of clinically T3 or T4 advanced gastric cancer were required to be under 75 years of age and to have adequate organ function.
  • After the curative resection of gastric cancer with D2 lymph node dissection and the reconstruction of the alimentary tract, HIPEC was carried out for 30 minutes with 50mg of CDDP, 10mg of MMC, and 1000mg of 5-FU in 5 L saline maintained at 42-43°C.
  • A total of 7 patients had postoperative complications such as continuous pancreatic juice secretion (13.8%), abdominal abscess (10.3%), leakage of the anastomosis (3.4%), and pulmonary insufficiency (10.3%).
  • CONCLUSIONS: The present study suggests that HIPEC with three drugs after curative resection of advanced gastric primary cancer is associated with improved overall survival with an acceptable morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U: Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e19089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • This single-arm, open-labeled phase II trial aims to evaluate the efficacy and safety profile of B in combination with another widely used chemotherapy doublet for NSCLC: cisplatin and vinorelbine.
  • 4 abdominal pain, 1 p. gr.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962195.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Hurwitz H, Patt YZ, Henry D, Garbo L, Mitchell EP, Kohles J, Spigel D: Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis.
  • Complete surgical resection was allowed using pre-defined criteria.
  • Other grade 3/4 toxicities (>5%, Q2W vs Q3W) included fatigue (13% vs 13%), dehydration (12% vs 10%), nausea (8% vs 9%), peripheral neuropathy (5% vs 9%), anorexia (5% vs 7%), and abdominal pain (5% vs 7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961632.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Tumor location (from anal verge): < 6 cm in 8pts, >6 cm in 7pts.
  • Surgery (performed in 14 patients) consisted of low anterior resection in 7pts and abdominal-perineal resection in 8pts.
  • Tumor down staging was observed in 9pts (60%), including 5pts with complete pathological response (33.3%).
  • CONCLUSIONS: Preliminary results show that preoperative concomitant chemoradiotherapy with Capecitabine is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • All patients underwent exploratory laparotomy, cytology, total abdominal hysterectomy and bilateral salpingoophorectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Santoro J, Yorke E, Rosenzweig K, Goodman K, McNamara J, Pham H, Mageras G: Abstracts. Med Phys; 2010 Jun;37(6Part12):3090-3469

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study compares respiration-correlated kV cone beam CT (RC-kVCBCT) image guidance to standard (uncorrelated) kVCBCT for target localization in radiation treatment of thoracic and abdominal tumors.
  • METHOD AND MATERIALS: In an IRB-approved study, 9 stage II-IV non-small cell lung cancer (NSCLC) patients and 1 stage III stomach tumor patient with fiducials received a respiration-correlated planning CT (RCCT) at simulation and five RC-CBCTs during the first week of treatment.
  • The tumor in each phase of the RC-CBCT is registered to the end-expiration (EE) phase image to obtain the respiration-averaged tumor displacement relative to its EE position.
  • The RCCT and RC-CBCT images at EE are registered to obtain the tumor displacement at the EE position.
  • A vector sum of the three displacements yields the correction to the respiration-averaged tumor position.
  • CONCLUSION: Our preliminary results suggest that for many thoracic and abdominal tumors, position corrections using uncorrelated, respiration-averaged 3D imaging are consistent with those from respiration-correlated imaging; however, respiration-correlated imaging may be indicated for cases of large tumor motion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512987.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed tomography / Cone beam computed tomography / Image reconstruction / Lungs / Medical image reconstruction / Medical imaging / Pneumodynamics / Radiation therapy / Radiation treatment
  •  go-up   go-down


55. Zhang Q, Hu YC, Liu F, Goodman K, Rosenzweig KE, Mageras GS: Correction of motion artifacts in cone-beam CT using a patient-specific respiratory motion model. Med Phys; 2010 Jun;37(6Part1):2901-2909

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Motion correction methods in CBCT have focused on the thorax because of its higher soft tissue contrast, whereas low-contrast tissue in abdomen remains a challenge.
  • The authors report on a method to correct respiration-induced motion artifacts in 1 min CBCT scans that is applicable in both thorax and abdomen, using a motion model adapted to the patient from a respiration-correlated image set.
  • In the thorax, the model is obtained from the same CBCT images that are to be motion-corrected, whereas in the abdomen, the model uses respiration-correlated CT (RCCT) images acquired prior to the treatment session.
  • The approximately 600 projection images are sorted into six (in thorax) or ten (in abdomen) subsets and reconstructed to obtain a set of low-quality respiration-correlated RC-CBCT images.
  • Repeated application of the model with different reference images produces a series of motion-corrected CBCT images over the respiration cycle, for determining the motion extent of the tumor and nearby organs at risk.
  • RESULTS: Evaluation in lung phantom, two patient cases in thorax and two in upper abdomen, shows that blurring and streaking artifacts are visibly reduced with motion correction.
  • Repeat application of the method in one thorax case, with reference images chosen at end expiration and end inspiration, indicates its feasibility for observing tumor motion extent.
  • CONCLUSIONS: Motion correction of CBCT is feasible and yields observable improvement in the thorax and abdomen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512947.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Calibration / Cancer / Computed tomography / Cone beam computed tomography / Eigenvalues / Lungs / Medical image artifacts / Medical imaging / Pneumodyamics, respiration / Reconstruction / Registration / Tissues / computerised tomography / cone-beam computed tomography / image reconstruction / image registration / image-guided radiation treatment / kidney / liver cancer / lung / lung cancer / medical image processing / organ motion / pneumodynamics / principal component analysis / tumours
  •  go-up   go-down


56. McMeekin DD, Lanneau G, Curiel J, Moore K, Walker J, Mannel R: Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers. J Clin Oncol; 2009 May 20;27(15_suppl):5540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers.
  • : 5540 Background: Excessive toxicity and difficulty in completing prescribed cycles are cited as factors behind the lack of routine acceptance of IP therapy in O/P cancer.
  • METHODS: An open label phase II study was conducted in patients (pts) with stage II-III O/P cancers with residual disease < 1 cm.
  • Of 20 evaluable pts, 2 pts discontinued prematurely (1 after cycle 1 due to elevated liver function tests, 1 after cycle 4 due to grade 3 neuropathy), and 1 pt received cycle 6 by IV route secondary to abdominal pain with IP infusion.
  • One patient developed a DVT, one had an intra-abdominal fistula requiring surgical intervention after cycle 6.
  • CONCLUSIONS: The addition of bevacizumab to an IP regimen for O/P cancers did not add to enhanced acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962516.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Wiffen PJ: Evidence-Based Pain Management and Palliative Care in Issue Three for 2007 of The Cochrane Library. J Pain Palliat Care Pharmacother; 2008;22(1):21-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-Based Pain Management and Palliative Care in Issue Three for 2007 of The Cochrane Library.
  • The Cochrane Library of Systematic Reviews is published quarterly.
  • Issue 3 2007 contains 3197 complete reviews, 1744 protocols for reviews in production and 6312 one-page summaries of systematic reviews published in the general medical literature.
  • In addition there are citations of 503,000 randomized controlled trials, and 9628 cited papers in the Cochrane methodology register.
  • The health technology assessment database contains 6817 citations.
  • This edition of the Library contains 103 new reviews of which 11 have potential relevance for practitioners in pain and palliative medicine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28792815.001).
  • [ISSN] 1536-0539
  • [Journal-full-title] Journal of pain & palliative care pharmacotherapy
  • [ISO-abbreviation] J Pain Palliat Care Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Abdominal pain / acetaminophen / anticoagulant / anxiety / burn injuries / central venous catheter / colorectal cancer / cryotherapy / incontinence / lidocaine / liver metastases / low back pain / paracetamol / prostate cancer / residential care / sacral nerve stimulation / therapeutic touch / thrombosis
  •  go-up   go-down


58. Tew WP, O'Cearbhaill R, Zhou Q, Thaler H, Konner J, Hensley ML, Sabbatini P, Spriggs D, Aghajanian C, Lichtman SM: Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC). J Clin Oncol; 2009 May 20;27(15_suppl):5541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC).
  • Toxicities included: 32% had IP port complications, 42% functional decline, 43% new ≥ Gr1 neuropathy (4% Gr3), 12% Gr2 hearing impairment, 60% ≥ Gr1 nausea/vomiting (4% Gr3), 57% ≥ Gr1 diarrhea/constipation (0% Gr3), 37% ≥ Gr1 abdominal pain (2% Gr3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Matuschek C, Bölke E, Gripp S, Budach W, Hermsen D, Peiper M: Mediator release during combined radio chemotherapy in rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):3043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3043 Background: Bacterial translocation is a well-documented phenomenon after polytrauma and major abdominal surgery.
  • Today neoadjuvant chemoradiotherapy is the gold standard for uT3, N+ rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961978.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol; 2009 May 20;27(15_suppl):4545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).
  • : 4545 Background: Gastric cancer (GC) with peritoneal metastasis (PM) often complicates ascites or intestinal stenosis and the prognosis is still poor.
  • Anti-cancer drugs generally can not be administered for such patients (pts) due to the risk of serious and prolonged adverse events.
  • Frequencies (%) of grade 4 neutropenia, grade >3 febrile neutropenia, infection with neutropenia, anemia, anorexia, diarrhea, abdominal pain within 6M, and treatment related death (5-FUci/MF) were 0/9, 0/3, 0/5, 10/16, 27/34, 1/10, 5/10 and 2/1, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Sakon M, Ikeda M: Venous thromboembolism in abdominal cancer surgery. Clin J Gastroenterol; 2009 Aug;2(4):247-251
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in abdominal cancer surgery.
  • Cancer, particularly adenocarcinoma developing in the digestive organs, is one of the most potent risk factors for VTE, as first described by Trousseau in 1865.
  • Cell membrane microparticles shedding from cancer cells play a critical role in venous clot formation through tissue factor (TF)-mediated activation of the coagulation system.
  • Since recent prospective studies have demonstrated that VTE risk in Japanese surgical patients is comparable to that in Caucasians, perioperative thromboprophylaxis with anticoagulants is now considered essential in patients undergoing abdominal cancer surgery, in addition to mechanical thromboprophylaxis.
  • Recent multi-center studies have also shown the efficacy and safety of enoxaparin, a low molecular weight heparin (LMWH), and fondaparinux, a synthetic Xa inhibitor, in VTE prevention after abdominal cancer surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • [Cites] Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):455-7 [15692260.001]
  • [Cites] Masui. 2007 Jul;56(7):758-9 [17633834.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1266-71 [15304029.001]
  • [Cites] Oncologist. 2003;8(4):381-8 [12897335.001]
  • [Cites] J Thromb Haemost. 2006 Mar;4(3):581-6 [16460440.001]
  • [Cites] Am J Med. 2006 Jan;119(1):60-8 [16431186.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] Chest. 2001 Jan;119(1 Suppl):132S-175S [11157647.001]
  • [Cites] Arch Intern Med. 1964 Mar;113:323-30 [14096382.001]
  • [Cites] Chest. 2003 Sep;124(3 Suppl):58S-68S [12970125.001]
  • [Cites] Int Angiol. 2001 Mar;20(1):1-37 [11342993.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jan;38(1):2-7 [18258711.001]
  • [Cites] Thromb Haemost. 2007 Oct;98(4):756-64 [17938798.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2870-5 [17504985.001]
  • [Cites] Breast Cancer Res. 2008;10(2):204 [18373885.001]
  • [Cites] Clin Orthop Relat Res. 2000 Jun;(375):168-74 [10853166.001]
  • [Cites] Int J Oncol. 1995 Apr;6(4):885-8 [21556616.001]
  • [Cites] Jpn J Clin Oncol. 2001 Aug;31(8):388-94 [11574632.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):862-8 [17103063.001]
  • [Cites] Surg Today. 2004;34(10):805-10 [15449147.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):240-4 [15224359.001]
  • [Cites] J Thromb Haemost. 2007 Jul;5 Suppl 1:246-54 [17635733.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):600-8 [10653875.001]
  • [Cites] Lancet. 2008 Feb 2;371(9610):387-94 [18242412.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1590-6 [16102023.001]
  • [Cites] Clin Hemorheol Microcirc. 2006;35(1-2):257-9 [16899938.001]
  • [Cites] Blood. 2008 Jan 1;111(1):190-9 [17901245.001]
  • (PMID = 26192418.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Digestive cancer / Thromboprophylaxis / Venous thromboembolism
  •  go-up   go-down


62. Senkal M, Haaker R, Linseisen J, Wolfram G, Homann HH, Stehle P: Preoperative Oral Supplementation with Long-Chain Ω-3 Fatty Acids Beneficially Alters Phospholipid Fatty Acid Patterns in Liver, Gut Mucosa, and Tumor Tissue. JPEN J Parenter Enteral Nutr; 2005;29(4):236-240

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative Oral Supplementation with Long-Chain Ω-3 Fatty Acids Beneficially Alters Phospholipid Fatty Acid Patterns in Liver, Gut Mucosa, and Tumor Tissue.
  • BACKGROUND: The uptake of ω-3 polyunsaturated fatty acids (PUFAs) into the liver, gut mucosa, and tumor tissue and plasma levels after preoperative administration of supplemented enteral nutrition was investigated in patients with malignancies of the upper gastrointestinal tract.
  • Tissue samples of liver, gut mucosa (small intestine), and tumor were taken during surgery and homogenized.
  • As compared with the control group, the PUFA group had significantly increased levels of EPA in liver tissue (0.4 vs 1.3 weight %), gut mucosa (0.3 vs 1.0 weight %), and tumor tissue (0.3 vs 0.8 weight %).
  • Also, the DHA levels in the PUFA group were significantly higher than the control group: liver tissue (4.1 vs 7.5 weight %), gut mucosa (2.1 vs 3.7 weight %) and tumor tissue (1.9 vs 4.2 weight %).
  • CONCLUSIONS: This study suggests that administration of PUFA-enriched diets leads to increased incorporation of EPA and DHA not only in liver and gut mucosa tissue, but also in tumor tissue in patients with solid gastrointestinal tumors.
  • Thus, preoperative administration of oral PUFA-enriched diets could have an impact on the postoperative inflammatory response after major abdominal surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28052736.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Chi PM, Balter P, Luo D, Mohan R, Pan T: Relation of external surface to internal tumor motion studied with cine CT. Med Phys; 2006 Sep;33(9):3116-3123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of external surface to internal tumor motion studied with cine CT.
  • The accuracy of delivering gated-radiation therapy to lung tumors using an external respiratory surrogate relies on not only interfractional and intrafractional reproducibility, but also a strong correlation between external motion and internal tumor motion.
  • The purpose of this work was to use the cine images acquired by four-dimensional computed tomography acquisition protocol to study the relation between external surface motion and internal tumor motion.
  • The respiratory phase information of tumor motion and chest wall motion was measured on the cine images using a proposed region-of-interest (ROI) method and compared to measurement of an external respiratory monitoring device.
  • On eight lung patient data sets, the phase shifts were measured between (1) the signal of a real-time positioning-management (RPM) respiratory monitoring device placed in the abdominal region and four surface locations on the chest wall, (2) the RPM signal in the abdominal region and tumor motions, and (3) chest wall surface motions and tumor motions.
  • Seven of the 8 patients showed the abdominal motion leading chest wall motion.
  • The best correlation (smallest phase shift) was found between the abdominal motion and the superior-inferior (S-I) tumor motion.
  • A wide range of phase shifts was observed between external surface motion and tumor anterior-posterior (A-P)/lateral motion.
  • The result supported the placement of the RPM block in the abdominal region and suggested that during a gated therapy utilizing the RPM system, it is necessary to place the RPM block at the same location as it is during treatment simulation in order to reduce potential errors introduced by the position of the RPM block.
  • Correlations between external motions and lateral/A-P tumor motions were inconclusive due to a combination of patient selection and the limitation of the ROI method.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2006 American Association of Physicists in Medicine.
  • (PMID = 28525068.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed radiography / Computed tomography / Drug delivery / Effects of ionizing radiation on biological systems / Error analysis / Hemodynamics / Lungs / Medical image reconstruction / Medical imaging / Pneumodyamics, respiration / Pneumodynamics / Pulmonary fluid mechanics / Real time information delivery / computerised tomography / four-dimensional computed tomography / lung / patient monitoring / phase shift / pneumodynamics / radiation therapy / respiratory motion / tumor motion / tumours
  •  go-up   go-down


64. Hompes D, D'Hoore A, Van Cutsem E, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Kerger J, Legendre H: Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study. J Clin Oncol; 2009 May 20;27(15_suppl):4101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study.
  • : 4101 Background: Up to 25% of patients with metastatic CRC present with peritoneal carcinomatosis (PC) as the only site of metastases.
  • In 72.9% of patients the primary tumor had been previously resected.
  • Median PCI (peritoneal cancer index) was 11 [1-22], with a median of 6 [1-11] abdominal regions involved and a median lesion size score of 3 [1-3].
  • Complication rate was 52.1%, with 18 intra- and 17 extra-abdominal complications.
  • Occurrence of intra-abdominal complications significantly affected hospital stay (p=0.0012), but no risk factors for occurrence of postoperative complications could be clearly identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Dumont AG, Lev D, Lazar A, Joensuu H, Trent J: Simultaneous gastrointestinal stromal tumor (GIST) and desmoid fibromatosis (DF). J Clin Oncol; 2009 May 20;27(15_suppl):10568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous gastrointestinal stromal tumor (GIST) and desmoid fibromatosis (DF).
  • Gastrointestinal Stromal Tumor (GIST) is the most common mesenchymal tumors of the gastrointestinal tract and also rare (15-20 cases per year per million).
  • Anecdotal reports of individuals with both diseases led us to investigate the number of patients at our institute with both types of cancer and their clinical, and histopathologic features.
  • Anderson Cancer Center between 1995 and 2008 using an IRB-approved protocol.
  • RESULTS: Our patients were three men and three women aged from 39 to 66.
  • The primary site of the GIST was gastric in 4 cases and the others were jejunal and mesenteric.
  • Three patients had their DF occur in the surgical incision site mimicking a recurrence of GIST.
  • The 3 others were intra-abdominal DF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963790.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Watkins WT, Li R, Lewis J, Park JC, Sandhu A, Jiang SB, Song WY: Patient-specific motion artifacts in 4DCT. Med Phys; 2010 Jun;37(6Part1):2855-2861

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Four-dimensional computed tomography (4DCT) has enhanced images of the thorax and upper abdomen during respiration, but intraphase residual motion artifacts will persist in cine-mode scanning.
  • It was determined that these motion artifacts depend on patient-specific tumor motion and CT gantry rotation speed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512952.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 4DCT / Cancer / Computed tomography / Image sensors / Lungs / Medical image artifacts / Medical image reconstruction / Medical imaging / Pneumodyamics, respiration / Pneumodynamics / Radiation therapy / Reconstruction / Time resolved imaging / X-ray imaging / biological organs / cancer / computerised tomography / image motion analysis / image reconstruction / intrafraction motion / lung / lung cancer / medical image processing / patient-specific margin / phantoms / pneumodynamics / tumours / uncertainty
  •  go-up   go-down


67. Salerrno May KS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M: Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e15532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal atrophy secondary to chemoradiation treatment of abdominal malignancies.
  • : e15532 Background: Information on renal atrophy following abdominal chemoradiation (CRT) is limited.
  • METHODS: Patients who received concurrent CRT to the abdomen between 2002 and 2008 were identified for this study to evaluate change in renal size (RS) and function following CRT.
  • RS was defined by craniocaudal measurement on CT images.
  • The primarily irradiated kidney (PK) was defined as the kidney that received the greater mean kidney dose.
  • CONCLUSIONS: Significant detriments in PK size and renal function were seen following abdominal CRT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Masciari S, Schrader KA, Senz J, Tung N, Balmana J, Razzak AR, Miron P, Huntsman DG, Garber JE: Prevalence of CDH1 germline mutations in subjects with early onset or familial lobular breast cancer, a multicenter collaboration. J Clin Oncol; 2009 May 20;27(15_suppl):11042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of CDH1 germline mutations in subjects with early onset or familial lobular breast cancer, a multicenter collaboration.
  • : 11042 Background: Invasive lobular breast carcinoma (LBC) is part of the hereditary diffuse gastric cancer (HDGC) syndrome, associated with germline mutations in the E-cadherin (CDH1) gene.
  • In this study, we estimated the prevalence of germline CDH1mutations among women with LBC who were either diagnosed at young age or had family history of breast cancer (BC).
  • METHODS: Germline DNA was collected from 383 women with LBC or mixed, lobular/ductal, BC from breast cancer programs, familial cancer clinics, and population-based cohorts.
  • No gastric cancers were reported in these families.
  • Given the difficulty of identifying CDH1 mutations from BC history alone and the importance of managing the gastric cancer risk in CDH1carriers, these findings should underscore the need to obtain an accurate abdominal cancer family history from women with LBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Ferrer Perez AI Jr, Vidal Losada MJ, Serrano Solares S, Tobeña Puyal M, Pajares Bernad I, Lopez Sanchez D, Ruiz-Echarri Rueda M, Millastre Bocos E, Lambea Sorrosal J, Tres Sanchez A: Evaluation of nausea, vomiting, and diarrhea in oncologic patients at the emergency department. J Clin Oncol; 2009 May 20;27(15_suppl):e20727

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20727 Background: Nausea, vomiting, and diarrhea are very common in cancer patients under palliative treatment.
  • The aim of this study is to describe cancer patient population which consults for nausea, vomiting, or diarrhea in the Emergency Department (ED) of a tertiary hospital, their causes and clinical management.
  • METHODS: From October 2007 to October 2008, all cancer patients attended at the Emergency Department of our hospital were prospectively collected.
  • The reasons for consultation, diagnosis and clinical management in the SE are described Results: Of 560 patients enrolled, 440 patients were stage IV disease.
  • The most frequent causes of these symptoms were chemotherapy toxicity (52.6%) and acute abdominal pathology (15.8%).
  • The most important etiology of these situations is the chemotherapy toxicity, followed by acute abdominal pathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962019.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Ito Y, Hatake K, Takahashi S, Yokoyama M, Suenaga M, Ota M, Onozawa Y, Yamazaki K, Hironaka S, Boku N: Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor measurements were made at screening and at the end of every 8 weeks (2 cycles) by RECIST.
  • Tumor types at primary diagnosis were advanced colorectal (81%), breast (14%), and gastric (5%) cancer.
  • Neratinib-related AEs, any grade in ≥25% of pts included diarrhea (95%), fatigue (67%), anorexia (43%), nausea (43%), abdominal pain (38%), decreased hemoglobin (38%), increased AST (33%), and rash (29%).
  • The 2 pts with PR had ErbB-2+ advanced breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Lee KS, Ro J, Park IH, Kim EA, Nam B: Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer.
  • : 1093 Background: Irinotecan (I) and capecitabine (X) have demonstrated single agent activity against breast cancer by different antitumor mechanism without cross-resistance.
  • To assess the objective response rate (RR) of IX combination in metastatic breast cancer (MBC) patients (pts) was the primary end point.
  • NCI grade ≥ 3 adverse events were: neutropenia (60%); asthenia, diarrhea, and vomiting (9%, each); transaminase elevation and febrile neutropenia (6%, each); abdominal pain, anorexia, fatigue, myalgia, and nausea (3%, each).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Tsujinaka T, Hirao M, Fujitani K, Mishima H, Ikenaga M, Sawamura T, Kurata M: Effect of preoperative immunonutrition on body composition in patients undergoing abdominal cancer surgery. Surg Today; 2007;37(2):118-21
MedlinePlus Health Information. consumer health - Dietary Proteins.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative immunonutrition on body composition in patients undergoing abdominal cancer surgery.
  • PURPOSE: Preoperative immunonutrition may induce changes that modulate stress responses and improve the outcome of patients undergoing abdominal cancer surgery.
  • METHODS: Forty patients aged 20-75 years, who were scheduled to undergo abdominal cancer surgery, were given Impact for 5 days preoperatively, at 1000 ml/day, in addition to a regular diet.
  • CONCLUSIONS: Preoperative immunonutrition was well tolerated by cancer patients.
  • [MeSH-major] Abdominal Neoplasms / diet therapy. Abdominal Neoplasms / surgery. Body Composition / physiology. Dietary Proteins / administration & dosage. Immunotherapy / methods. Preoperative Care / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243029.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dietary Proteins
  •  go-up   go-down


73. Blackstock AW, Aklilu M, Lovato J, Degrass L, Sommer J, Howerton R, Mishra G, Levine E, McQuellon R: Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/ 5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/ 5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer.
  • : e20661 Background: Significant chemoradiation-induced nausea and vomiting (CRINV) occurs in patients (pts) receiving chemoradiation for pancreatic cancer.
  • METHODS: Pts with locally advanced or resected pancreatic cancer received wkly Gemcitabine (200 mg/m2) and continuous infusion 5-fluorouracil (5-FU) or oral capecitabine with concurrent radiation (50.4 Gy).
  • The Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) questionnaire was completed at baseline prior to the start of all therapy, Time 1 (T#1), repeated at the end of the first week (T#2) and then repeated again at the end of the last full week of chemoradiation (T#3).
  • CONCLUSIONS: Prophylactic Aprepitant/5HT-3/dexamethasone therapy resulted in minimal CRINV for pts receiving upper abdominal chemoradiation in this feasibility study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961720.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Pineda C, Cadogan KV, Cadogan MA: Distribution of metastases in NSCLC: Economic impact of imaging. J Clin Oncol; 2009 May 20;27(15_suppl):e19036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given that many patients have metastases to several organs, one important question is - "what is the frequency of metastases in the chest, the abdomen, the pelvis, elsewhere?
  • RESULTS: We found that there were 690 metastases to the chest, 205 to the abdomen, 80 to the bones, 18 to the pelvis, 13 to the brain and 23 others, not specified.
  • SEER Cancer Statistics Review, 1975-2005.
  • National Cancer Institute. 03JAN2009. http://seer.cancer.gov/csr/1975_2005/ .].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Ströhlein M, Lordick F, Rüttinger D, Schemanski O, Jaeger M, Lindhofer H, Hennig M, Lahr A, Heiss M: Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):3033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up.
  • : 3033 Background: Peritoneal carcinomatosis (PC) from gastrointestinal (GI) cancer is associated with a poor outcome.
  • The trifunctional antibody catumaxomab may induce remission by redirecting T-lymphocytes and Fcγ-receptor I/III positive accessory cells to tumor cells.
  • METHODS: Patients with epithelial cell adhesion molecule (EpCAM)-positive PC from GI cancer were enrolled in a multicenter phase I study and received four sequential intraperitoneal catumaxomab infusions on days 0, 3, 7, and 10 at increasing doses.
  • The most common drug-related adverse events at the MTD were fever, vomiting, abdominal pain, skin toxicity, and nausea.
  • Median survival from the time of diagnosis of PC was 502 days in study patients versus 180 days in control patients (log-rank p = .0083).
  • Elimination of tumor cells from peritoneal lavage samples, delayed disease progression, and prolonged survival indicate that intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Senkal M, Geier B, Hannemann M, Deska T, Linseisen J, Wolfram G, Adolph M: Supplementation of Ω-3 Fatty Acids in Parenteral Nutrition Beneficially Alters Phospholipid Fatty Acid Pattern. JPEN J Parenter Enteral Nutr; 2007;31(1):12-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, postoperative parenteral administration of ω-3-PUFA-enriched lipid emulsions could have an impact on the postoperative inflammatory response after abdominal surgery and could be used in standard postoperative care when PN is indicated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28052726.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Quintela-Fandino MA, Young A, Webster S, Grewal M, Wang L, Moore MJ, Krzyzanowska M, Mak TW, Siu LL: Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination with metronomic cyclophosphamide (mC) in advanced neuroendocrine tumors (aNET). J Clin Oncol; 2009 May 20;27(15_suppl):3526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • S doses (mg BID) at cycle 1 were 200 (2 pt)/400 (5)/600 (2)/800 (1); corresponding cycle 1 day 1RAF STC I (%) were 5, 53/94, 100, 95, 16, 65/25, 41/71, respectively (R<sup>2</sup> = 0.13 p = 0.72) Most frequent Gr 3 non-hematologic possibly related adverse events in 30 cycles: hand-foot (2 pt), hypertension, abdominal pain, diarrhea, vomiting, lipase, ileal perforation (1 each).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961320.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Gallagher DJ, Milowsky MI, Gerst SR, Tickoo S, Ishill N, Ishill N, Regazzi A, Trout A, Bajorin DF: A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol; 2009 May 20;27(15_suppl):5072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically significant toxicity (Grade 3/4) included: abdominal pain (1), anorexia (1), diarrhea (1), fatigue (4), hand and foot syndrome (2), hemorrhage (2), hypertension (2), mucositis (2), thrombosis (2), and emesis (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964257.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Magnan HD, Chou T, LaQuaglia MP, Gerald W, Ladanyi M, Merchant MS: Elevated expression of VEGFR-2 and VEGFA in desmoplastic small round cell tumor (DSRCT) and activity of bevacizumab and irinotecan in a xenograft model of DSRCT. J Clin Oncol; 2009 May 20;27(15_suppl):10016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated expression of VEGFR-2 and VEGFA in desmoplastic small round cell tumor (DSRCT) and activity of bevacizumab and irinotecan in a xenograft model of DSRCT.
  • : 10016 Background: Desmoplastic small round cell tumor (DSRCT) is an aggressive tumor with poor response to multimodality therapies.
  • METHODS: RNA was extracted from frozen tumor samples (DSRCT, alveolar soft part sarcoma, alveolar rhabdomyosarcoma, synovial sarcoma, and Ewing sarcoma) and a human DSRCT cell line, JN-DSRCT.
  • A primary tumor developed within 8 - 12 weeks with concomitant development of abdominal metastases.
  • Mice were treated during primary tumor growth with bevacizumab (5ug/kg IP weekly), irinotecan (2.5mg/kg IP ×10 days q3 weeks), or a combination of both.
  • RESULTS: Microarray data demonstrated an average of 4.5 times higher RNA expression of VEGFR-2 (KDR) in DSRCT tumor samples as compared to the other translocation-associated sarcomas (p = 3.6 E-12).
  • VEGFA was also highly overexpressed in the DSRCT line and tumor samples when compared to the other translocation-associated sarcomas (2.5 times, p = 1.1E-10).
  • Taken together, the expression data and the sustained response of DSRCT xenografts to bevacizumab suggest that VEGF-dependent angiogenesis is important for DSRCT tumor biology and represents an attractive target for therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962501.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Campos LT, Nemunaitis J, Stephenson J, Richards D, Barve M, Gardner L, Niecestro R, Sportelli P: Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):e15505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grade 3/4 drug-related toxicities > 10% included: abdominal pain (12%), elevated liver enzymes (10%) and fatigue (10%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962225.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Walji N, Zachariah A, Yap C, Hussain SA, Poole CJ, El-Modir A, Ganesan R, Fernando IN: Carboplatin, ifosfamide, and mesna (CIM) for the treatment of gynecological carcinosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16539 Background: A GOG trial comparing cisplatin/ifosfamide/mesna chemotherapy versus whole abdominal irradiation for FIGO stages I-IV carcinosarcoma (CS) showed an estimated median survival (MS) of 50 months for chemotherapy but high toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Laheru D, Rudek M, Taylor G, Goldsweig H, Rajeshkumar NV, Linden S, Angenendt M, Le D, Donehower R, Jimeno A, Hidalgo M: Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer.
  • : 4529 Background: The Ras signaling pathway stands as a strategic target in pancreatic cancer.
  • Here we studied the activity of this agent in patients with advanced pancreatic cancer.
  • METHODS: Patients with treatment naïve advanced peri-ampullary cancer were treated with gemcitabine (Gem) administered at standard dose and schedule + FTS administered orally at doses of 200-800 mg bid 21 days of a 28 day cycle.
  • Patients were treated until progression or protocol defined DLT.
  • The most common adverse events were neutropenia, anemia, abdominal cramping, elevated liver function tests and diarrhea.
  • 4. Salirasib mechanism of Ras inhibition is confirmed by reduction of tumor Ras in pancreatic cancer patients.
  • 5. Salirasib warrants evaluation in a controlled study with gemcitabine in pancreatic cancer; doses of 600 or 400 mg b.i.d. are recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962713.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Schaller C, Penne J, Hornegger J: Time-of-flight sensor for respiratory motion gating. Med Phys; 2008 Jul;35(7Part1):3090-3093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this technical note we present a system that uses time-of-flight (ToF) technology to acquire a real-time multidimensional respiratory signal from a 3D surface reconstruction of the patient's chest and abdomen without the use of markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28513021.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 4D reconstruction / Biological signal processing / Calibration / Cameras / Emission spectra / Image sensors / Interpolation / Medical imaging / Movement sensors / Pneumodyamics, respiration / Real time information delivery / Time of flight mass spectrometry / Tracking devices / gating / markerless noncontact respiratory tracking / medical signal detection / pneumodynamics / surface reconstruction / time-of-flight
  •  go-up   go-down


84. Ford NL, Nikolov HN, Norley CJD, Thornton MM, Foster PJ, Drangova M, Holdsworth DW: Prospective respiratory-gated micro-CT of free breathing rodents. Med Phys; 2005 Sep;32(9):2888-2898

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, motion artifacts associated with the normal respiratory motion of the animal may arise when imaging the abdomen or thorax.
  • Anaesthetized animals were placed in the prone position on the bed with their abdomens located over the chamber.
  • The respiratory wave form was monitored and recorded simultaneously with the x-ray radiation pulses, and an imaging window was defined, beginning at end expiration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28523770.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Computed radiography / Digital image processing / Digital radiography / Hemodynamics / Image quality / Lungs / Medical X-ray imaging / Medical image quality / Medical image reconstruction / Medical imaging / Pneumodyamics, respiration / Pneumodynamics / Transducers / X-ray imaging / biological organs / computerised tomography / data acquisition / diagnostic radiography / in vivo imaging / micro computed tomography / phantoms / pneumodynamics / pressure transducers / respiratory gating / respiratory organ movement / small animal imaging
  •  go-up   go-down


85. Brady S, Yoshizumi T, Toncheva G, Frush D: Implementation of radiochromic film dosimetry protocol for volumetric dose assessments to various organs during diagnostic CT procedures. Med Phys; 2010 Sep;37(9):4782-4792

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a similar manner, TLDs and films were placed between cross-sectional slabs of a 5 yr old anthropomorphic phantom's thorax and abdomen regions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524581.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / CT dosimetry / Computed tomography / Computer software / Dosimetry / GafChromic XRQA / Kidneys / Liver / Lungs / Medical imaging / Radiochromic film / Standards and calibration / TLD dosimetry / Thermoluminescent dosimeters / Tissues / biological tissues / calibration / computerised tomography / dosimetry / kidney / liver / lung / phantoms / thermoluminescent dosimeters / two-dimensional dosimetry
  •  go-up   go-down


86. Jimeno A, Hong DS, Hecker S, Clement R, Kurzrock R, Pestano LA, Hiscox A, Leos RA, Kirkpatrick DL, Eckhardt SG, Herbst RS: Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):3542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PX-866 is being evaluated in a phase 1 clinical trial to determine the MTD, and measure safety, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in PBMCs and tumor tissue in patients with solid tumors.
  • METHODS: Patients with advanced metastatic cancers receive PX-866 orally once daily for 5 of 7 days for 2 weeks in a 28-day cycle.
  • Once the MTD of this PX-866 schedule of administration has been identified, an expansion cohort is planned to investigate tumor PD events and correlate tumor and PBMC endpoints with efficacy.
  • Abdominal discomfort and mild diarrhea have been possibly associated with PX-866.
  • Two patients (squamous cell skin cancer and melanoma) had decrease in pain allowing discontinuation of analgesics.
  • PX-866 has shown to have a mild side effect profile while inducing stabilization of disease in previously progressing cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961356.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Vergote IB, Colombo N, Kutarska E, Del Campo J, Pippitt C, Casado A, Lengyel E, Gilder K, Ho S, Schilder RJ: Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer.
  • A Phase I/II study was performed to evaluate PLD with/without V in patients (pts) with recurrent ovarian or primary peritoneal cancer that relapsed after platinum/taxane-based chemotherapy (maximum 2 prior lines).
  • The most common Grade 3/4 AEs (≥5% in any group) were abdominal pain, intestinal obstruction, ascites, fatigue, hypoalbuminemia, and cytopenias.
  • Analyses correlating PFS with platinum sensitivity and α5β1 tumor expression are ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962571.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Marcy P Sr, Chamorey E, Macchiavello J, Largillier R, Peyrade F, Ferrero J, Hanoun-Levi J, Poudenx M, François E, Frenay M: Distal or proximal venous port device insertion: Results of a prospective randomized trial. J Clin Oncol; 2009 May 20;27(15_suppl):e20605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligibility criteria included adult patients with solid tissue malignancy (neuro oncology, gynecology, lung, abdominal, head§neck) beginning a course of I.V.chemotherapy, normal hemostatic parameters, no organ failure, a life expectancy >3months, WHO status<3.
  • Exclusion criteria included current anticoagulant therapy, previous ipsilateral venous catheter/pacewires/surgical axillary node dissection/radiodermatitis, local tumor growth/sepsis, symptomatic brain metastasis, psychosis.
  • Distal (arm port) technique should be recommended in young female cancer patients (neckline cosmesis/discretion), head and neck cancer patients, obese patients (upright position) and in patients presenting with respiratory insufficiency or at high risk for pneumothorax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961555.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Pua T, Novetsky AP, Blank SV: Use of Child-Pugh score to assess perioperative outcome in epithelial ovarian cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):5571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Child-Pugh score to assess perioperative outcome in epithelial ovarian cancer patients.
  • Epithelial ovarian cancer (EOC) and cirrhosis share manifestations of increased abdominal girth, ascites, malnutrition and abnormal laboratory findings.
  • Of note there were 4 peri-operative deaths, all in the B/C group (p = 0.01).
  • CONCLUSIONS: Application of the Child classification to women with ovarian cancer revealed increased rates of suboptimal cytoreduction and peri-operative complications including ICU admission, infection, transfusion and death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962611.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Kindler HL, Garbo L, Stephenson J, Wiezorek J, Sabin T, Hsu M, Civoli F, Richards D: A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):4501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).
  • : 4501 Background: AMG 655 is an investigational, fully human agonist monoclonal antibody (IgG1) that binds human death receptor 5 (DR5), activates caspases, and induces apoptosis in sensitive tumor cells.
  • Nine (69%) pts had grade 3-4 toxicity, the most common were: thrombocytopenia (4 pts), neutropenia (2 pts), and abdominal pain (2 pts).
  • CONCLUSIONS: AMG 655 + G is well-tolerated and may have activity in metastatic pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962691.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Lu W, Low DA, Parikh PJ, Nystrom MM, El Naqa IM, Wahab SH, Handoko M, Fooshee D, Bradley JD: Comparison of spirometry and abdominal height as four-dimensional computed tomography metrics in lung. Med Phys; 2005 Jul;32(7Part1):2351-2357

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of spirometry and abdominal height as four-dimensional computed tomography metrics in lung.
  • This study compared two noninvasive breathing metrics, spirometry and abdominal height, against internal air content, used as a surrogate for internal motion.
  • Both metrics were shown to be accurate, but the spirometry showed a stronger and more reproducible relationship than the abdominal height in the lung.
  • The abdominal height was known to be affected by sensor placement and patient positioning while the spirometer exhibited signal drift.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28493581.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed radiography / Computed tomography / Height measurements / Hemodynamics / Intensity modulated radiation therapy / Lungs / Medical imaging / Movement sensors / Pneumodyamics, respiration / Position sensitive detectors / Radiation therapy / Tissues / abdominal height / biomedical measurement / breathing motion / computerised tomography / lung / pneumodynamics / radiation therapy / spirometry
  •  go-up   go-down


92. Al-Niaimi A, Manuelli B, Safdar N, Chappell R, Seo S, Kushner D, Connor J, Hartenbach E: Survival with surgical versus medical treatment of patients with bowel obstruction secondary to ovarian cancer recurrence: A 15-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival with surgical versus medical treatment of patients with bowel obstruction secondary to ovarian cancer recurrence: A 15-year experience.
  • : e16515 Background: To compare the impact of surgical versus medical management on the survival of patients presenting with small bowel obstruction (SBO) secondary to recurrent ovarian cancer.
  • METHODS: The Institutional Review Board approved a retrospective chart review of all patients with SBO due to recurrent ovarian cancer at the University of Wisconsin Hospital between January 1, 1992, and December 31, 2007.
  • The data abstracted from patient charts included demographics, primary cancer characteristics, detailed clinical information at the time of SBO, management strategy, and outcome.
  • 86% of the patients had stage III/IV ovarian cancer, while 14% had stage I/II.
  • The median time from tumor recurrence to bowel obstruction was 17 months.
  • Patients without abdominal or pelvic mass on CT had a median survival of 60 months; patients with any mass noted had a median survival of 3.6 months; patients with liver and lung metastases was 3 months (p = 0.001).
  • CONCLUSIONS: In patients with bowel obstruction due to ovarian cancer recurrence; early stage at diagnosis, the absence of ascites, and lack of abdominal/pelvic mass or distant metastases significantly lengthens survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. De La Mota J, Thomas B, Fengwei W, Micaily B, Yajue H, Hernandez E: Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):e16578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC).
  • : e16578 Background: Stage IB1 CC is treated with radical abdominal hysterectomy (RH) and pelvic lymph node dissection (LND) because of presumed risk of parametrial and nodal involvement.
  • Median tumor diameter of patients without lymphovascular space involvement (LVI), with LVI, and with positive LN was 1.2, 2.0, and 2.5 cm respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Mullen JT, Davenport DL, Hutter MM, Hosokawa PW, Henderson WG, Khuri SF, Moorman DW: Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. Ann Surg Oncol; 2008 Aug;15(8):2164-72
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of body mass index on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery.
  • We sought to determine the impact of body mass index (BMI) on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery.
  • METHODS: A prospective, multi-institutional, risk-adjusted cohort study of patients undergoing major intra-abdominal cancer surgery was performed from the 14 university hospitals participating in the Patient Safety in Surgery Study of the National Surgical Quality Improvement Program (NSQIP).
  • Patients were stratified by National Institutes of Health (NIH)-defined BMI obesity class, with 573 (25.4%) patients classified as obese (BMI > 30 kg/m(2)).
  • CONCLUSION: In patients undergoing major intra-abdominal cancer surgery, obesity is not a risk factor for postoperative mortality or major complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18548313.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Saleh MN, Pitot H, Maleski J, Leopold L, Forero A: Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers.
  • : e14537 Background: Over-expression of Bcl-2 family proteins is common in human cancers.
  • In this study different dosing schedules of AT-101 were tested in adults with advanced cancers and final results for the pulse dosing schedule of twice a day for three days every other week (b.i.d. x 3d EOW) are being reported.
  • Grade 3-4 AEs occurring in > 2 pts include: nausea, abdominal pain, elevated AST (3 pts each), vomiting, fatigue, dehydration (4 pts each), hypokalemia (5 pts).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Kakimoto K, Ono Y, Meguro N, Takezawa K, Yoshida T, Arai Y, Usami M: Stage I nonseminomatous germ cell tumors of the testis: Clinical outcome of 45 patients on a surveillance protocol after orchiectomy alone at a single institution in Japan. J Clin Oncol; 2009 May 20;27(15_suppl):e16165

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16165 Background: In Japan, risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis (NSGCTT) has been performed in very few institutions.
  • The patients were monitored at follow-up evaluation for tumor marker (AFP, beta-hCG) levels and by abdominal CT scan, chest x-ray, and physical examination.
  • Primary testis tumor samples were assessed for prognostic factors including lymphatic and/or vascular (LV) invasion and pathological components such as the presence of embryonal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Moroney JW, Coleman RL, Hong DS, Wheler JJ, Ng C, Bodurka DC, Falchook G, Naing A, Helgason T, Kurzrock R: A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy. J Clin Oncol; 2009 May 20;27(15_suppl):e13508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At first restaging, 2/2 patients with endometrial cancer were found to have ≥ 25% decrease in tumor size (RECIST), and one patient with colorectal carcinoma had a 15% decrease.
  • One of the patients with endometrial cancer and extensive intra-abdominal disease who showed rapid tumor regression (≥ 25% decrease at 2 months) developed an entero-colonic fistula, and chose hospice care.
  • CONCLUSIONS: Preliminary data indicate that the combination of D, A and T has anti-tumor activity and is well tolerated at the doses used.
  • Patients with intra-abdominal disease who experience rapid tumor regression may be at risk for fistula formation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kopf A, Bätjer N: [Pain management in gastrointestinal oncology]. Z Gastroenterol; 2005 Sep;43(9):1061-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal cancer is commonly associated with pain needing medical attention.
  • With adequate implementation of therapeutic guidelines into clinical practice including the use of co-analgesics, adjuvants and non-pharmacological treatment options the quality of life of abdominal cancer patients can be considerably improved.
  • [MeSH-major] Abdominal Pain / etiology. Abdominal Pain / prevention & control. Analgesics, Opioid / therapeutic use. Gastrointestinal Neoplasms / complications. Palliative Care / methods. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142615.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  • [Number-of-references] 84
  •  go-up   go-down


99. Kehlet H, Laurberg S: [Gastrointestinal surgery--why specialisation?]. Ugeskr Laeger; 2006 Apr 10;168(15):1519-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nation-wide Danish data have documented a high mortality and long hospital stay after abdominal cancer surgery, which is performed in a large number of departments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640969.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


100. Sakamoto H, Kitano M, Kamata K, Komaki T, Imai H, Chikugo T, Takeyama Y, Kudo M: EUS-guided broad plexus neurolysis over the superior mesenteric artery using a 25-gauge needle. Am J Gastroenterol; 2010 Dec;105(12):2599-606
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Endoscopic ultrasonography (EUS)-guided celiac plexus neurolysis (EUS-CPN) is safe and effective but not beneficial for some patients with extended abdominal cancer.
  • RESULTS: A total of 67 patients with advanced abdominal cancer were included (34 EUS-CPN and 33 EUS-BPN).
  • CONCLUSIONS: Our preliminary data suggested that EUS-BPN using a 25-gauge needle provides patients with advanced abdominal cancer with better pain relief than standard EUS-CPN, and without incurring serious complications.
  • [MeSH-major] Abdominal Neoplasms / complications. Abdominal Pain / etiology. Abdominal Pain / therapy. Autonomic Nerve Block / methods. Celiac Plexus. Endosonography. Needles. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2010 Dec;105(12):2607-9 [21131929.001]
  • (PMID = 20823834.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down






Advertisement